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Available online 17 May 2016Purpose: The aim of this studywas to determinewhether categories of contraception differ in their impact on sei-
zures in women with epilepsy and whether the impact varies by antiepileptic drug category.
Methods: Retrospective survey data came from 2712 contraceptive experiences reported by 1144 women with
epilepsy. We compared risk ratios for reports of increase and decrease in seizure frequency on hormonal versus
nonhormonal contraception, stratiﬁed by antiepileptic drug categories.
Results:More women with epilepsy reported a change in seizures on hormonal (28.2%) than on nonhormonal
contraception (9.7%) (p b 0.0001). The risk ratio for seizure increase on hormonal (18.7%) versus nonhormonal
contraception (4.2%) was 4.47 (p b 0.0001). The risk ratio for seizure decrease on hormonal (9.5%) versus non-
hormonal contraception (5.5%) was 1.71, p b 0.0001. On hormonal contraception, the risk ratio for seizure
increase was greater than for decrease (1.98, p b 0.0001). In comparison to combined pills, both hormonal
patch and progestin-only pills had greater risk ratios for seizure increase. Depomedroxyprogesterone was the
only hormonal method with a greater risk ratio for seizure decrease than combined pills. Seizure increase was
greater for hormonal than nonhormonal contraception for each antiepileptic drug category (p b 0.001). On
hormonal contraception, relative to the non-enzyme-inducing antiepileptic drug category which had the lowest
rate, each of the other categories had signiﬁcantly greater risks for seizure increase, especially the enzyme-
inhibiting (valproate) category (risk ratio = 2.53, p = 0.0002).
Conclusion: The ﬁndings provide community-based, epidemiological survey evidence that contraceptive
methods may differ in their impact on seizures and that this impact may vary by antiepileptic drug category.
© 2016 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Epidemiology1. Introduction
The Epilepsy Birth Control Registry (EBCR) is a large-scale, web-based
survey investigation of the contraceptive practices ofwomenwith epilep-
sy in the community [1]. Initial exploratory ﬁndings suggest that approx-
imately one-half of women with epilepsy (WWE) at risk of unplanned
pregnancy use hormonal contraception (HC) [1]. The widespread use of
HC by this population raises questions regarding seizure safety since
some reproductive steroids have neuroactive properties that can affect
neuronal excitability and seizure thresholds [2–12]. Moreover, reciprocal
pharmacological interactions occur between some reproductive steroids
and some antiepileptic drugs (AEDs) that may compromise both contra-
ceptive efﬁcacy and seizure control [13–19]. Nevertheless, large-scale,e Unit, Beth Israel Deaconess
sley, MA 02481, United States.
zog).
en access article under the CC BY-NCcommunity-based clinical studies comparing the seizure safety of hor-
monal contraception to other categories of contraception with typical
use inWWE are lacking as are comprehensive evidence-based guidelines
for the selection of optimal, safe, and effective contraceptive methods for
this special population. The purpose of this part of the EBCR project was
to determine whether there is a differential impact of various categories
of contraception on seizure frequency in WWE in the community and,
if so, whether the impact varies when stratiﬁed by AED category.
2. Methods
2.1. Subjects
The subjects were the ﬁrst 1144 WWE who completed the EBCR
web-based survey. Individuals were directed to the survey from various
referral sources such as epilepsy organizationwebsites, socialmedia, in-
ternet searches, and study brochures posted in clinics. Participation in
the study required that women be of reproductive age, be between 18-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Frequencies of seizure increase and decrease on various single-method categories of
contraception.
Number of
contraceptive
experiences (2424)
Number of reports
of seizure increase
(%)
Number of reports of
seizure decrease (%)
Withdrawal 352 18 (5.1%) 12 (3.4%)
Barrier 711 21 (3.0%) 27 (3.8%)
Hormonal 1094 218 (19.9%) 111 (10.1%)
IUD 228 14 (6.1%) 30 (13.2%)
Tubal ligation 39 2 (5.1%) 6 (15.4%)
Data are the frequencies of responses to the question “Do you think that this method of
birth control changed how often you had seizures?” Combinations of contraceptive
methods (N= 288) are presented separately.
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of 18were excluded because of the difﬁculty in ascertaining the consent
of minors and their guardians online. Detailed demographic, epilepsy,
and AED characteristics of the EBCR population have been published
in a report of their contraceptive practices [1].
This study was approved by theWestern Institutional Review Board
as well as the Columbia University Medical Center Institutional Review
Board. Online consent was obtained from all participants. This study
was carried out in accordance with The Code of Ethics of the World
Medical Association (Declaration of Helsinki) for experiments involving
humans.
2.2. Data collection and deﬁnitions
These retrospective data came from 2712 contraceptive experiences
reported by the ﬁrst 1144WWEwho completed the online EBCR survey.
Contraceptive methods were broadly classiﬁed as systemic hormonal
(HC) (which included oral-combined or progestin-only contraceptive
pills, patches, vaginal ring, depomedroxyprogesterone, and implanted
progestins) versus nonhormonal (NHC) (which included withdrawal,
male and female condoms, copper and progestin intrauterine devices,
and tubal ligation). This broad classiﬁcation was parceled further into
more speciﬁc categories (withdrawal, barrier, hormonal [subcategories:
oral, non-oral, combined, progestin-only], intrauterine device [subcate-
gories: copper, progestin], and tubal ligation). Categories were identiﬁed
as single-method (e.g., hormonal) or combination (e.g., hormonal and
withdrawal). Combinations were designated as hormonal if they
included the use of systemic hormones.
We categorized AED treatment as none, monotherapy, or
polytherapy. We grouped AEDs into 6 categories based on their effects
on enzymatic metabolism: 1) no AED; 2) enzyme-inducing AEDs which
included phenobarbital, phenytoin, carbamazepine, oxcarbazepine, and
topiramate (N200 mg daily); 3) glucuronidated AEDs which included
only lamotrigine; 4) non-enzyme-inducing AEDs which included leveti-
racetam, zonisamide, gabapentin, topiramate (in dosages ≤200 mg
daily), and lacosamide, clobazam, pregabalin, and tiagabine; 5) en-
zyme-inhibiting AEDs which included only valproate; and 6) mixed cat-
egories. Note that valproate was listed in the enzyme-inhibiting AED
category although it is also partially glucuronidated. When there was a
combination of an AED that affected enzymes and a non-enzyme-induc-
ing AED, the combination was listed by the category that affected en-
zymes. If the combination was comprised of two or more categories
that affect enzymes differently, they were listed as mixed category.
Seizure outcomedatawere the frequencies of “increase”, “decrease”,
and “no change” responses to the question “Do you think that this
method of birth control changed how often you had seizures?”
Deﬁnitions have been published in greater detail previously [1]. Since
there was a congruence of over 99% between the directional changes
in seizure frequency and seizure severity, we present only the results
for seizure frequency.
2.3. Outcomes
The studywas designed to address 4 speciﬁc questions regarding the
safety of the contraceptive practices of WWE as they relate to seizures:
1. Do the frequencies of reports of changes in seizure frequency differ
by the broad categories of HC versus NHC?
2. Are there differences in the frequencies of reports of changes in
seizure frequency among the various more speciﬁc categories of
contraception (withdrawal, barrier, hormonal, intrauterine device,
and tubal ligation) and subcategories of hormonal contraception
and intrauterine devices?
3. Are frequencies of reports of changes in seizure frequency on HC and
NHC affected by the category of AED in use?4. What are the odds of seizure increase or decrease on various combi-
nations of contraceptive and AED categories?
2.4. Statistical analysis
We determined whether there were differences in the proportions
of WWE who reported seizure change on the broad class of HC versus
NHC using Χ2 analysis (SPSS v23). We compared the risk ratios (RRs)
of reports of seizure increase and decrease on HC versus NHC, as well
as on the 5 more speciﬁc contraceptive categories, using the category
with the least impact on seizure frequency as referent. Risk ratios are
reported with their 95% CI in parentheses. We carried out separate
comparisons for single-method and combination-method categories.
We determined whether there were differences in the proportions
of WWE who reported seizure change on the broad class of HC versus
NHC, stratiﬁed by the ﬁrst 5 (i.e., nonmixed) AED categories, using Χ2
analysis.We comparedmixed categories and various AED combinations
separately. We determined and compared the RRs for seizure increase
and decrease by AED category, separately for HC and NHC, using no
AED and also the AED category with the lowest rate of seizure increase
and decrease as referent.
We carried out predictor analyses using binary logistic regression
separately for seizure increase and decrease, using the categories of
contraception and the categories of AEDs, as well as their interactions,
as predictor variables. We compared predictor probabilities using odds
ratios (ORs).
3. Results
3.1. Differential effects of hormonal versus nonhormonal contraception on
seizures
Although the majority of WWE reported no change in seizure fre-
quency with the use of HC (934/1300, 71.8%) and NHC (1275/1412,
90.3%), more WWE reported a change in seizures on HC than NHC
(366/1300, 28.2% versus 137/1412, 9.7%; Χ2 = 152.53, df = 1,
p b 0.0001). The RR for seizure increase on HC (243/1300, 18.7%) versus
NHC (59/1412, 4.2%) was 4.47 (3.40–5.89) (p b 0.0001). The RR for sei-
zure decrease on HC (123/1300, 9.5%) versus NHC (78/1412, 5.5%) was
1.71 (1.30-2.25), p b 0.0001. Although the RRs for both seizure increase
and decrease are greater with HC than NHC, the RR for seizure increase
on HC was greater than for decrease (RR = 1.98 (1.61–2.42),
p b 0.0001), whereas on NHC, there was no signiﬁcant difference
(RR = 0.76 (0.54–1.05), p = NS).
3.2. Differential effects of the various categories and subcategories of
contraception on seizures
Table 1 lists the frequencies of seizure increase and decrease by the
various single-method categories of contraception. The lowest rate of
seizure increase was reported with barrier methods (3.0%), whereas
the highest occurred with systemic hormonal methods (19.9%). Fig. 1
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Fig. 1. The risk ratio (RR) for reports of seizure increase was substantially and signiﬁcantly
greater with hormonal contraception than with each of the categories of nonhormonal
contraception. In comparison to barrier, which had the lowest rate at 3.0%, hormonal
contraception had a RR of 6.75 (95% CI: 4.35–10.45) (p b 0.0001).
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relative to barrier, the one with the lowest rate. The RR for seizure in-
crease was signiﬁcantly (p b 0.05) and substantially greater with HC
than with each of the categories of NHC. The greatest RRwas for HC rel-
ative to barrier (6.75 [4.35–10.45], p b 0.0001).
Table 2 lists the frequencies of seizure increase and decrease by the
various subcategories of HC. In comparison to the combined pill,
which was the most frequently used method and had the lowest rate
of reports of seizure increase in the broad HC category, both hormonal
patch (RR = 1.68 [1.11–2.56], p = 0.01) and progestin-only pill
(RR = 1.62 [1.05–2.49], p = 0.03) had greater RRs for seizure increase.
Depomedroxyprogesterone (35/200, 17.5%) was the only HC method
with a greater RR for seizure decrease than combined pill (57/635,
9.0%) (RR = 1.95 (1.32–2.88), p = 0.0008).
In a comparison of combinations of contraceptive methods, combi-
nations that included HC (25/206, 12.1%) showed a greater RR for sei-
zure increase than those consisting only of NHC (4/82, 4.9%). The RR
was 2.49 (0.89-6.93) (p = 0.0811).
With regard to seizure decrease (Table 1), relative to withdrawal
which had the lowest rate of seizure decrease (12/352, 3.4%), the RRs
for seizure decrease were greater with tubal ligation (RR = 4.51
[1.79–11.35], p = 0.001), intrauterine device (RR = 3.86 [2.02–7.38],
p b 0.0001), and HC (RR=2.98 [1.66–5.33], p=0.0002) but not barrier
(RR = 1.11 [0.57–2.17], p = NS).
In a comparison of combinations of contraception methods for sei-
zure decrease, frequencies of decrease were small and did not show a
signiﬁcant difference (HC combinations (12/206, 5.8%) versus NHC
(3/82, 3.7%); RR = 1.59 [0.46–5.50], p = NS).
There were no signiﬁcant differences in RRs between progestin and
copper intrauterine devices for seizure increase (progestin (10/150,
6.7%) versus copper (4/78, 5.1%); RR = 1.30 [0.42–4.01], p = NS) orTable 2
Comparisons of subcategories and types of hormonal contraception effects on seizures.
Combined
Oral Combined OCP
Non-oral
Vaginal ring
Hormonal patch
Progestin-only
Oral Progestin OCP
Non-oral
Progestin implant
DMPA
In comparison to combined oral contraceptive pill (OCP), themost commonly used hormonal co
patch (RR = 1.68 [95% CI = 1.11–2.56], p = .01) and progestin-only oral contraceptive pi
depomedroxyprogesterone (DMPA) (RR = 1.95 [95% CI = 1.32–2.88], p = 0.0008).decrease (progestin (22/150, 14.7%) versus copper (8/78, 10.3%);
RR = 1.43 [0.6677–3.0625], p = NS).
3.3. Differential effects of hormonal versus nonhormonal contraception on
seizures, stratiﬁed by antiepileptic drug category
The frequencies of reports of seizure increase were greater for HC
than NHC for each AED category at the p b 0.001 level: no AED
[28/148 (18.9%) versus 1/85 (1.2%)], enzyme-inducing AED [53/311
(17%) versus 9/385 (2.3%)], glucuronidated AED [53/291 (18.2%) versus
12/344 (3.5%)], non-enzyme-inducing AED [27/232 (11.6%) versus
6/224 (2.7%)], and enzyme-inhibiting AED [25/85 (29.4%) versus 2/79
(2.5%)] (Fig. 2). The mixed category also showed a greater frequency
of seizure increase on HC [39/137 (28.5%)] than on NHC [13/191
(6.8%)] (p b 0.0001).
The frequencies of reports of seizure increase differed by AED cate-
gory for HC (p = 0.032) but not for NHC (p = NS) (Table 3). The fre-
quencies of seizure decrease did not differ signiﬁcantly by AED
category for HCorNHC (Table 3). Relative to the frequency of seizure in-
crease reported by WWE for no AED on HC (18.9%), the RR for seizure
increase on enzyme-inhibiting AED (29.4%) trended greater (RR =
1.55 (0.97–2.48), p= 0.065), whereas the RR for non-enzyme-inducing
AED (11.6%) was less (RR = 0.62 (0.38–1.00), p = 0.05). Relative to
non-enzyme-inducing AED (the category that had the lowest frequency
of seizure increase on HC (11.6%)), all of the other AED categories
showed greater RRs for seizure increase: enzyme-inhibiting AED
(RR = 2.53 (1.56–4.10), p = 0.0002), glucuronidated AED (RR = 1.57
(1.02–2.41), p = 0.04), and enzyme-inducing AED (RR = 1.46 (0.95-
2.25), p = 0.08). Although seizure decrease did not differ signiﬁcantly
for AED categories relative to no AED on HC, non-enzyme-inducing
AED (the category which had the highest frequency of seizure decrease
on HC (11.6%)) had a RR that was almost twofold greater than for
glucuronidated AED, which had the lowest frequency (6.2%) (RR =
1.89 (1.06–3.33), p = 0.03).
Each AED category showed a greater frequency of reports of seizure
increase than decrease on HC except the non-enzyme-inducing AED
category: no AED (RR = 2.00 (1.10–3.64), p = .02), enzyme-inducing
AED (RR = 1.56 (1.04–2.33), p = 0.03), glucuronidated AED (RR =
2.80 (1.69–4.66), p = 0.0001), non-enzyme-inducing AED (RR = 1.00
(0.61–1.65), p = NS), and enzyme-inhibiting AED (RR = 4.17 (1.80–
9.64), p = 0.0009) (Table 3). There was no signiﬁcant difference be-
tween reports of seizure increase and decrease for any AED category
on NHC.
Among AED monotherapies, valproate had the most notable differ-
ential effect on HC versus NHC. In 69 experiences on valproate with
HC, there were 22 (31.9%) reports of seizure increase as compared to
no reports (0.0%) of seizure increase in 60 experiences on valproate
with NHC (Fisher's exact test: p b 0.0001). In contrast, seizure decrease
was very similar on HC and NHC: 3/69 (4.3%) on valproate with HC ver-
sus 2/60 (3.3%) on valproate with NHC (Fisher's exact test: p = NS).
Next came lamotrigine: in 183 experiences on lamotrigine monothera-
py with HC, there were 42 (23.0%) reports of seizure increase as com-
pared to 8/223 (3.6%) on lamotrigine with NHC (Fisher's exact test:N Seizure increase (%) Seizure decrease (%)
635 115 (18.1%) 57 (9.0%)
104 21 (20.2%) 7 (6.7%)
59 18 (30.5%) 5 (8.5%)
58 17 (29.3%) 5 (8.6%)
37 9 (24.3%) 2 (5.4%)
200 38 (19.0%) 35 (17.5%)
ntraceptivemethod, therewas a greater risk ratio (RR) for seizure increasewith hormonal
ll (RR = 1.62 [95% CI = 1.05–2.49], p = .03) and greater RR for seizure decrease with
2.2% 3.6% 2.3% 2.5%
18.9%
17.0% 18.2%
11.6%
29.4%
0%
10%
20%
30%
40%
No AED EIAED GluAED NEIAED InhAED
Fr
eq
ue
nc
y 
of
 S
ei
zu
re
 In
cr
ea
se
AED Category
Non-Hormonal (N = 1076)
Hormonal (N = 1067)
1.3%
Fig. 2. The frequency of reports of seizure increasewas signiﬁcantly greater (p b 0.001) for
hormonal contraception than nonhormonal contraception for each AED category
(EIAED — enzyme-inducing AED, GluAED — glucuronidated AED [lamotrigine],
NEIAED — non-EIAED, InhAED — enzyme-inhibiting AED [valproate], and no AED).
Mixed categories are not included. AED categories differed in the frequencies of reports
of seizure increase on hormonal contraception (p = 0.032) but not on nonhormonal
contraception (p = NS). Abbreviations: EIAED = enzyme-inducing AED, GluAED =
glucuronidated AED [lamotrigine], NEIAED = non-EIAED, InhAED = enzyme-inhibiting
AED [valproate]. Mixed categories are analyzed separately.
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cantly for lamotrigine on HC versus NHC: 7/183 (3.8%) on lamotrigine
with HC versus 8/223 (3.6%) on lamotrigine with NHC (Fisher's exact
test: p = NS). In a comparison of the two most common AEDs in the
non-enzyme-inducing AED category, although levetiracetam had the
more favorable proﬁle, there were no signiﬁcant differences between
levetiracetam and zonisamide for seizure increase (levetiracetam
(14/124, 11.3%) versus zonisamide (7/42, 16.7%)) or decrease (leveti-
racetam (11/124, 8.9%) versus zonisamide (2/42, 4.8%)).
Among the AED combinations on HC, only glucuronidated
AED + enzyme-inhibiting AED showed a signiﬁcantly greater RR forTable 3
Frequencies of reports of changes in seizure frequency on hormonal contraception,
stratiﬁed by AED category.
N on
HC
Seizure
increase on
HC (%)
Seizure
decrease on
HC (%)
N on
NHC
Seizure
increase on
NHC (%)
Seizure
decrease on
NHC (%)
No AED 148 28 (18.9%) 14 (9.5%) 85 1 (1.2%) 3 (3.5%)
EIAED 311 53 (17.0%) 34 (10.9%) 385 9 (2.3%) 21 (5.5%)
GLUAED 291 53 (18.2%) 18 (6.2%) 344 12 (3.5%) 12 (3.5%)
NEIAED 232 27 (11.6%) 27 (11.6%) 223 6 (2.7%) 15 (6.7%)
InhAED 85 25 (29.4%) 6 (7.1%) 79 2 (2.5%) 4 (5.1%)
AED categories differed in the frequencies of reports of seizure increase on hormonal con-
traception (Χ2 = 14.270, df = 4, p = 0.006) but not on nonhormonal contraception. The
frequency of reports of seizure decrease did not differ signiﬁcantly among AED categories
on either HC or NHC. Relative to the frequency of seizure increase reported byWWE for no
AED onhormonal contraception (18.9%), the risk ratio (RR) for seizure increase on InhAED
(29.4%) trended greater (RR = 1.55 (0.97–2.48), p = 0.065), whereas the RR for NEIAED
(11.6%) was less (RR= 0.62 (0.38–1.00), p = 0.05). Relative to NEIAED, the category that
had the lowest frequency of seizure increase on HC (11.6%), all of the other AED categories
showed greater RRs for seizure increase: InhAED (RR = 2.53 (1.56–4.10), p = 0.0002),
GluAED (RR = 1.57 (1.02–2.41), p = 0.04), and EIAED (RR = 1.46 (10.95–2.25), p =
0.08). NEIAED, the category which had the highest frequency of seizure decrease on HC
(11.6%), had a RR that was almost twofold greater than for GluAED, which had the lowest
frequency (6.2%) (RR= 1.89 (1.06–3.33), p= 0.03). Each AED category showed a greater
frequency of seizure increase than decrease on HC except the non-enzyme-inducing AED
category: no AED (RR = 2.00 (1.10–3.64), p = .02), enzyme-inducing AED (RR = 1.56
(1.04–2.33), p=0.03), glucuronidated AED (RR=2.80 (1.69–4.66), p=0.0001), non-en-
zyme-inducing AED (RR= 1.00 (0.61–1.65), p = NS), and enzyme-inhibiting AED (RR=
4.17 (1.80–9.64), p=0.0009). Therewas no signiﬁcant difference for any AED category on
NHC. Abbreviations: HC = systemic hormonal contraception, NHC = nonhormonal con-
traception, AED = antiepileptic drug, EIAED = enzyme-inducing AED, GluAED =
glucuronidated AED [lamotrigine], NEIAED = non-EIAED, InhAED = enzyme-inhibiting
AED [valproate]. Mixed categories are analyzed separately.seizure increase than no AED (42.3% versus 18.9%) (RR = 2.24 (1.28–
3.91), p = 0.005).
3.4. Predictors of seizure increase and decrease on various combinations of
contraception and antiepileptic drug categories
Binary logistic regression analysis showed that contraception
category (p b 0.001) and interaction between contraception and AED
categories (p b 0.001) were signiﬁcant predictors of seizure increase.
Using barrier (the contraceptive category with the lowest rate at 3.0%)
as referent, HC was the only category with a signiﬁcantly greater prob-
ability (OR = 12.829 (95% CI: 6.713–24.518, p = b0.001)). This is con-
sistent with the ﬁnding reported above and in Fig. 1 for the RRs for
seizure increase. Each AED category showed a signiﬁcant interaction
with HC but not with any of the NHC categories. In comparison to the
combination of barrier and no AED, probabilities for seizure increase
were as follows: HC and enzyme-inhibiting AED (valproate) (OR =
9.046 (5.016–16.312), p b 0.001), HC and glucuronidated AED
(lamotrigine) (OR = 4.572 (2.859–7.310), p b 0.001), HC and en-
zyme-inducing AEDs (OR = 4.051 (2.559–6.415), p b 0.001), and HC
and non-enzyme-inducing AED (OR = 3.022 (1.764–5.179), p b 0.001).
Binary logistic regression also showed an interaction between con-
traception category and AED category as a predictive factor for seizure
decrease (p = 0.006). Probabilities again were signiﬁcant for interac-
tions between AED categories and HC (p b 0.01) but not NHC categories.
Probabilities for interaction between HC and AED categories relative to
the barrier and no AED category were as follows: HC and non-
enzyme-inducing AED (OR = 3.896 (1.762–8.618), p = 0.001), HC
and enzyme-inducing AED (OR = 2.950 (1.384–6.286), p = 0.005),
HC and glucuronidated AED (lamotrigine) (OR = 2.271 (0.994–5.191),
p = 0.052), and HC and enzyme-inhibiting AED (valproate) (OR =
1.039 (0.225–4.790), p = 0.961).
4. Discussion
4.1. Differential effects of contraceptive methods on seizures
Although the majority of WWE in the EBCR report no change in
seizure frequency with the use of any category of contraception, more
WWE experience changes on HC than on NHC. The RRs for both seizure
increase and decrease are greater with HC than NHC, with seizure
increase predominating. On HC, the RR is greater with hormonal patch
and progestin-only pills thanwith combined pills. The RR for seizure de-
crease is greater with depomedroxyprogesterone than with combined
pills.
Despite the widespread use of HC, there is a paucity of evidence re-
garding the neuroactive properties of the synthetic steroid constituents
of HC. With regard to ethinyl estradiol, one study on electroshock
seizure thresholds in female rats found that, although synthetic proges-
tins did not have a signiﬁcant effect, coadministration with ethinyl
estradiol signiﬁcantly lowered the seizure threshold [20]. Another
study found that the administration of ethinyl estradiol for 14 days to
female mice lowered hippocampal-kindled seizure thresholds and
increased seizure severity [21]. Ethinyl estradiol may also increase
seizure severity in the baboon [22]. Whereas natural progesterone
increases the serum and cerebral levels of allopregnanolone (a potent
allosteric agonist of the GABAA receptor [8–12]) and shows efﬁcacy
(class III evidence) in the treatment of perimenstrually exacerbated sei-
zures [23], synthetic progestins lower the serum and cerebral cortical
levels of allopregnanolone, change GABAA receptor subunit expression,
and produce anxiety-like behavior in a female rat model [24]. Synthetic
progestins have not shown efﬁcacy in seizure management except
when used in dosages which result in amenorrhea [25].
There are reasons to consider that the differential effects of contra-
ceptive categories on seizure frequency may reﬂect biological causes
rather than just reporting bias. A biological effect of HC on seizures is
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HC. Combined pills carried the lowest risk for seizure increase among
HC subcategories. The highest risk occurred with the hormonal patch,
the only subcategory which is known to produce substantially higher
serum levels of ethinyl estradiol than combined pills [26,27]. Speciﬁcal-
ly, the patchproduces 60%higher serumethinyl estradiol levels than the
35-μg ethinyl estradiol-containing combined pills. Since ethinyl estradi-
ol has proconvulsant properties [20–22], the higher ethinyl estradiol
concentration produced by the patch may account for its signiﬁcantly
greater risk for seizure increase.
In contrast, depomedroxyprogesterone, known to reduce seizure
frequency when used in dosages which produce amenorrhea [25], was
associated with a substantially greater risk for seizure decrease than
combined pills. Note, however, that depomedroxyprogesterone was
associated with somewhat more reports of seizure increase than
decrease (19% versus 17%). It remains to be determined whether the
difference in directional response of seizures might be related to partial
versus total suppression of ovarian estradiol secretion. For example, if
estradiol has a proconvulsant effect [2–7], it is possible that the use of
a standard regimen of depomedroxyprogesterone treatment might
produce only partial estradiol suppression when used with an
enzyme-inducing AED as compared to complete estradiol suppression
when used with a non-enzyme-inducing AED, resulting in an increase
in seizures with an enzyme-inducing AED yet a decrease with a non-
enzyme-inducing AED. The current EBCR ﬁndings do not yet have
enough statistical power to address this point conclusively. The impor-
tance of the level of estrogen suppression is also raised by the ﬁnding
that the contraceptive progestin-only pills, which have low progestin
content and exert contraceptive action more by the thickening of
cervical mucus rather than by hormonal suppression, had greater RRs
for seizure increase, not decrease, in comparison to combined pills.
The EBCR did not obtain data regarding the progestin-only pill dosages
used by participants and, therefore, cannot conclude whether the sub-
stantially higher dose progestin-only pills, which are used in the treat-
ment of endometriosis and abnormal vaginal bleeding because they
suppress ovarian steroid production, might differ in their effects on
seizures and mimic depomedroxyprogesterone rather than the typical
contraceptive progestin-only pills.
With regard to intrauterine device and tubal ligation, which had
signiﬁcantly higher frequencies of reports of seizure decrease than
withdrawal which had the lowest frequency, 20 of 30 (66.7%) WWE
who reported seizure decrease on intrauterine device and 5 of 6
(83.3%) WWE who reported seizure decrease on tubal ligation had
also used HC. Since HC is associated with more reports of seizure
increase than any other category, it is difﬁcult to determine whether
reports of seizure decrease on intrauterine device and tubal ligation
represent an actual protective effect of these categories versus an im-
provement relative to seizure increase that WWE may have experi-
enced with the use of HC. In favor of the latter explanation is the
ﬁnding that amongWWE on intrauterine device, 50% of the HC experi-
ences were associated with reports of seizure increase as compared to
only 18.7% on HC for WWE in the EBCR overall.
4.2. Differential impact of antiepileptic drugs on the contraceptive effects on
seizures
The EBCR ﬁndings suggest that AED categories differ in their impact
on the effects of HC on seizure frequency. An enzyme-inhibiting AED
(valproate) may pose the highest risk and non-enzyme-inducing AED,
the lowest risk for seizure increase on HC. Among combinations of
AEDs, glucuronidated AED + enzyme-inhibiting AED, the two AED
categories which have lower serum levels on active combined pills
[14,28], likely because of the hepatic induction of glucuronidation by
estrogen, may pose a higher risk than no AED on HC.
Seizure increase was signiﬁcantly more likely to occur on each AED
category in combination with HC than with NHC. On HC, the risk forseizure increase was greater for the enzyme-inhibiting category,
speciﬁcally valproate, than for any other AED category. This ﬁnding is
a potentially important clinical issue that requires further investigation
and, if true, demonstration of a pathophysiological mechanism.
Hormonal contraception lowers glucuronidated AED serum levels [14].
This has been demonstrated for valproate, as well as lamotrigine [28].
The lowering of AED levels, however, would not be an entirely adequate
explanation since lamotrigine levels are found to drop more than
valproate with HC [28], yet the rates of seizure increase with HC are
greater when combined with valproate (29.4%) than with lamotrigine
which had a rate very similar to no AED (18.2% versus 18.9%) in the
EBCR population. Another consideration is that these AEDs may have
differential effects on contraceptive hormone levels. Whereas
lamotrigine has an insigniﬁcant lowering effect on ethinyl estradiol
levels [19],might the enzyme-inhibiting valproate possibly raise ethinyl
estradiol levels in women, resulting in a proconvulsant effect? There is,
as yet, no conclusive evidence in WWE. One study of ethinyl estradiol
levels on combined pills before and after introduction of valproate ther-
apy in 6 healthy female controls reported higher peak and area-under-
the-curve levels of ethinyl estradiol on valproate, but the difference was
signiﬁcant only for peak levels [29]. Of note, higher serum estradiol
levels on valproate treatment have also been reported to occur in a
study of men with epilepsy as compared to healthy controls [30]. Of
course, the impact of valproate may relate to changes in the concentra-
tions of other neuroactive steroids not under consideration here.
The non-enzyme-inducing AED category had the highest frequency
of reports of seizure decrease. It had the highest and most signiﬁcant
probability for seizure decrease in comparison to other AED categories,
relative to noAEDon barrier. It was the only category that did not have a
signiﬁcantly greater frequency of seizure increase than decrease on HC,
and seizure decrease was signiﬁcantly greater than for glucuronidated
AED. While the ﬁnding that the lowest frequency of reports of seizure
decrease occurred on glucuronidated AED could be due to the induction
of glucuronidation by ethinyl estradiol, we found no signiﬁcant differ-
ence in the frequency of reports of seizure decrease between WWE on
progestin-only pills as compared to combined pills at this juncture of
the study. Likewise, although levetiracetamhad amore favorable proﬁle
than zonisamide for both seizure increase and decrease, the differences
were not signiﬁcant.
4.3. Seizure safety of hormonal contraception for women with epilepsy
Although large-scale, community-based, epidemiological studies
have been lacking, published reviews have stated that there is no
evidence that oral contraceptives increase seizure activity [31,32].
While the EBCR retrospective survey results are consistent with this
opinion as it pertains to the majority of WWE, the EBCR ﬁnds that HC
is associated with a broader range of seizure responses than NHC.
More speciﬁcally, a substantial minority of WWE may experience a
change in seizure frequency with HC, either increase or decrease, with
increase predominating. The HC outcome, moreover, may vary by AED
category. On HC, non-enzyme-inducing AEDs had the most favorable
proﬁle and enzyme-inhibitingAED (valproate), theAED that historically
has been listed among the AEDs that are appropriate to usewith HC, the
least. Although the methodology of ascertainment of data may contrib-
ute some level of bias to the EBCR ﬁndings [1], we present some plausi-
ble pathophysiological mechanisms by which HC and HC–AED
interactionsmight impact seizure frequency. The EBCR ﬁndings suggest
a need for prospective investigation of the impact of various AED cate-
gories on the differential effects of hormonal contraception on seizures.
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